Melanie Schürz leads our Research Program Line 3 – Nanovesicular Technologies – where we are developing a comprehensive catalog of theralytic methodologies for NV characterization and quality control, their tracking in vivo, and for biomarker discovery.

Melanie completed her Master and Doctoral degree at the University of Salzburg, during which she was working on oxidative stress in the liver, focusing on HNE- modified proteins and lipofuscin. Additional research areas include cell biological projects aiming the assessment of environmental toxicity in Kosovo. 2019 she joined the research group of Nicole Meisner-Kober as a research assistant.

Since January 2025 she leads the RG3 for Nanovesicular Technologies.